Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Publication
, Journal Article
Shingleton, JR; Dave, SS
Published in: J Clin Oncol
January 10, 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
January 10, 2020
Volume
38
Issue
2
Start / End Page
166 / 168
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, Large B-Cell, Diffuse
- Immunoconjugates
- Humans
- Antibodies, Monoclonal
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shingleton, J. R., & Dave, S. S. (2020). Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol, 38(2), 166–168. https://doi.org/10.1200/JCO.19.02587
Shingleton, Jennifer R., and Sandeep S. Dave. “Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” J Clin Oncol 38, no. 2 (January 10, 2020): 166–68. https://doi.org/10.1200/JCO.19.02587.
Shingleton JR, Dave SS. Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):166–8.
Shingleton, Jennifer R., and Sandeep S. Dave. “Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” J Clin Oncol, vol. 38, no. 2, Jan. 2020, pp. 166–68. Pubmed, doi:10.1200/JCO.19.02587.
Shingleton JR, Dave SS. Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):166–168.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
January 10, 2020
Volume
38
Issue
2
Start / End Page
166 / 168
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, Large B-Cell, Diffuse
- Immunoconjugates
- Humans
- Antibodies, Monoclonal
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences